Clinical Trials Browser

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease, Recurrence

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Hodgkin Disease

Hodgkin Disease, Recurrence

Lymphoma, Large B-Cell, Diffuse

Lymphoma, T-Cell, Peripheral

Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Advanced Solid Tumor

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Recurrence, Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

OLYMPIA-4

waveLINE-003

TERZO

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

FIL_A-BEGEV

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Study of Lacutamab in Peripheral T-cell Lymphoma

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma